Stoke Therapeutics Inc. (STOK)
25.60
-1.01 (3.80%)
Upcoming Events
Latest Headlines
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 16, 2026 4:20 PM - BizWire
Stoke Therapeutics shares STK-002 data for eye disorder at AAO
October 12, 2026 8:00 AM - StreetInsider
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
October 12, 2026 8:00 AM - BizWire
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Ann
October 6, 2026 8:00 AM - BizWire
Stoke Therapeutics meets with FDA on Dravet syndrome drug NDA
October 5, 2026 7:00 AM - StreetInsider
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
October 5, 2026 7:00 AM - BizWire
Form 4 Stoke Therapeutics, Inc. For: Oct 02 Filed by: Allan Jonathan
October 2, 2026 5:38 PM - SEC Filing
Form 4 Stoke Therapeutics, Inc. For: Oct 01 Filed by: Ticho Barry
October 2, 2026 5:36 PM - SEC Filing
Form 144 Stoke Therapeutics, Inc. Filed by: Allan Jonathan
October 2, 2026 4:21 PM - SEC Filing
Form SCHEDULE 13G Stoke Therapeutics, Inc. Filed by: BIOTECHNOLOGY VALUE FUND L P
September 30, 2026 6:31 PM - SEC Filing
Form 4 Stoke Therapeutics, Inc. For: Sep 23 Filed by: Cumbo Alexander
September 25, 2026 4:13 PM - SEC Filing
Form 3 Stoke Therapeutics, Inc. For: Sep 23 Filed by: Cumbo Alexander
September 25, 2026 4:10 PM - SEC Filing
Form 8-K Stoke Therapeutics, Inc. For: Sep 22
September 25, 2026 4:06 PM - SEC Filing
Stoke Therapeutics adds Bo Cumbo to its board of directors
September 23, 2026 4:02 PM - StreetInsider
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
September 23, 2026 4:01 PM - BizWire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
September 16, 2026 4:01 PM - BizWire
Goldman Sachs Reiterates Buy Rating on Stoke Therapeutics (STOK) Post Investor Meeting
September 10, 2026 4:57 AM - StreetInsider
Stoke, Biogen share 4-year data on zorevunersen for Dravet syndrome
September 4, 2026 6:00 AM - StreetInsider
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t
September 3, 2026 7:30 PM - StreetInsider
Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress
September 1, 2026 7:30 AM - StreetInsider
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Cong
September 1, 2026 7:30 AM - StreetInsider
JPMorgan Reinstates Stoke Therapeutics (STOK) at Overweight
August 21, 2026 3:28 AM - StreetInsider
Form 4 Stoke Therapeutics, Inc. For: Aug 14 Filed by: Ticho Barry
August 18, 2026 8:30 PM - SEC Filing
Form 4 Stoke Therapeutics, Inc. For: Aug 14 Filed by: Kaye Edward M. MD
August 18, 2026 8:29 PM - SEC Filing
Form 4 Stoke Therapeutics, Inc. For: Aug 14 Filed by: Allan Jonathan
August 18, 2026 8:27 PM - SEC Filing
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 18, 2026 4:01 PM - BizWire
Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: Lynx1 Capital Management LP
August 14, 2026 4:40 PM - SEC Filing
Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: TORONTO DOMINION BANK
August 12, 2026 4:10 PM - SEC Filing
Form SCHEDULE 13G/A Stoke Therapeutics, Inc. Filed by: FMR LLC
August 6, 2026 10:42 AM - SEC Filing
Form 4 Stoke Therapeutics, Inc. For: Aug 03 Filed by: Ticho Barry
August 5, 2026 4:22 PM - SEC Filing
Stoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth Conference
August 5, 2026 8:00 AM - BizWire
Stoke Therapeutics (STOK) PT Lowered to $58 at Canaccord
August 4, 2026 6:44 AM - StreetInsider
Form 8-K Stoke Therapeutics, Inc. For: Aug 03
August 3, 2026 5:06 PM - SEC Filing
Form 424B5 Stoke Therapeutics, Inc.
August 3, 2026 5:04 PM - SEC Filing
Form 144 Stoke Therapeutics, Inc. Filed by: Ticho Barry
August 3, 2026 4:49 PM - SEC Filing
Stoke Therapeutics, Inc. (STOK) Misses Q2 EPS by 16c
August 3, 2026 4:41 PM - StreetInsider
Form S-8 Stoke Therapeutics, Inc.
August 3, 2026 4:40 PM - SEC Filing
Form 10-Q Stoke Therapeutics, Inc. For: Jun 30
August 3, 2026 4:08 PM - SEC Filing
Form 8-K Stoke Therapeutics, Inc. For: Aug 03
August 3, 2026 4:06 PM - SEC Filing
Stoke Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Updates
August 3, 2026 4:01 PM - BizWire
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2026 Business and Financial Updates
July 27, 2026 4:01 PM - BizWire
Full Article List
